Fact Sheet: Oxytetracycline Immersion INAD 9033

for detailed information, see INAD study protocol, use link on the left

The following links are specific to:
Oxtetracycline Immersion

Drug summary & history

List of FDA-Approved drugs

Drug forms to be completed

Examples of completed forms

INAD study protocol

Material Safety Data Sheet
(MSDS)

Study Summaries

What's the status of this drug's
approval

Print this drug fact sheet

Print all drug fact sheets

INAD signup form (Federal facilities)

INAD signup form (other facilities)

Information on EPA's National Pollutant Discharge Elimination System (NPDES) Permits

Objective/purpose: Collect supportive and pivotal data needed to establish the effectiveness of oxytetracycline (OTC) immersion therapy to control mortality caused by certain bacterial diseases.
Drug name: Terramycin-343®
Source of drug: Pfizer, Inc.
Address: Pfizer Animal Health
700 Portage Road
RIC-190-43
Kalamazoo, MI 49001-0199
Contact:

Dr. Mark Subramanyam
Phone: 269-833-3388
Fax: 269-833-2707
Email: mark.subramanyam@pfizer.com

Target pathogen(s): Bacterial pathogens susceptible to oxytetracycline.
Method of administration: Immersion treatment
Treatment dosage: Options A & B: single treatment of 20 milligrams OTC per liter
Options C & D: up to multiple treatments at 20 milligrams OTC per liter
Treatment regimen: Option A: 1-hour treatment for salmonids
Option B
:
1-hour treatment for various cool and warmwater fish
Option C: 1-hour treatment on 1 to 4 consecutive days for salmonids
Option D:
1-hour treatment on 1 to 4 consecutive days for various cool and warmwater fish
Withdrawal period:

Options A & B: 21 days. No withdrawal period is required for fish that will not be catchable for 21 or more days after release, or are illegal for harvest.
Options C & D: 60 days. No withdrawal period is required for fish that will not be catchable for 60 or more days after release, or are illegal for harvest.

Required test parameters: Investigator must collect mortality data throughout the 5-day pretreatment, treatment, and 30-day posttreatment periods. Investigator should also report general fish behavior and any adverse effects relating to treatment.
Limitations or restrictions on use:

Investigator must follow all instructions in the Study Protocol for INAD 9033 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements.

Drug discharge must be in compliance with local NPDES permitting requirements.

Required INAD fee: $400.00 per facility per year
AADAP contact for other information: Ms. Bonnie Johnson, FWS - AADAP
Phone: 406-994-9905
Fax: 406-582-0242

bonnie_johnson@fws.gov
Disclaimer: Product and company names mentioned in this website, or mentioned in materials accessed via this website, are for informational purposes only. The mention of such does not imply endorsement by the Aquatic Animal Drug Approval Partnership, the U.S. Fish & Wildlife Service or any other organization of the U.S. Government.